We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dako, Amgen Expand Collaboration
News

Dako, Amgen Expand Collaboration

Dako, Amgen Expand Collaboration
News

Dako, Amgen Expand Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dako, Amgen Expand Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

"We are pleased to continue our work with Amgen, particularly within the molecular arena," said Jacob Thaysen, vice president and general manager for Agilent's Diagnostics and Genomics business. “We are excited to expand this collaboration into even more projects.”

The cutting-edge IQFISH hybridization buffer, introduced by Dako in 2012, reduces diagnostic test turnaround time from 17 hours to just 3.5 hours. It enables pathology labs—for the first time—to run DNA-based hybridization assays quickly, with distinct and higher fluorescent signal intensity compared to traditional FISH assays. This ability represents a major advance for pathologists, oncologists and ultimately patients.

Companion diagnostics are becoming increasingly important in treating disease. They provide a way to both improve patient care and reduce health-care costs by matching specific therapies to the individuals most likely to benefit from them, since all patients do not respond in the same way.

Dako partners with top-tier pharma companies for the development of companion diagnostics. Its track record in companion diagnostics continues to attract new partners, as well as add new projects with current partners.

Advertisement